BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | GILEAD SCIENCES INC | ||
EQ 50MG BASE;200MG;EQ 25MG BASE,EQ 30MG BASE;120MG;EQ 15MG BASE | |||
Yes | No | ||
2036-Nov-08 | 2023-Feb-07 | ||
None | None | ||
None | No | ||
BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY. |
0 | 1 | 0 |
Total Other Developers | 14 |
---|
Drugs with Suitability | No |
---|
EQ 50MG BASE;200MG;EQ 25MG BASE | ** | ** | Up | - | - |
EQ 30MG BASE;120MG;EQ 15MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com